Search results for "030211 gastroenterology & hepatology"

showing 10 items of 1275 documents

Action of low doses of Aspirin in Inflammation and Oxidative Stress induced by aβ1-42 on Astrocytes in primary culture

2020

Aspirin has been used as anti-inflammatory and anti-aggregate for decades but the precise mechanism(s) of action after the presence of the toxic peptide Aβ1-42 in cultured astrocytes remains poorly resolved. Here we use low-doses of aspirin (10-7 M) in astrocytes in primary culture in presence or absence of Aβ1-42 toxic peptide. We noted an increase of cell viability and proliferation with or without Aβ1-42 peptide presence in aspirin treated cells. In addition, a decrease in apoptosis, determined by Caspase 3 activity and the expression of Cyt c and Smac/Diablo, were detected. Also, aspirin diminished necrosis process (LDH levels), pro-inflammatory mediators (IL-β and TNF-α) and NF-ᴋB prot…

chemistry.chemical_classificationAspirinNecrosisbiologyCytochrome cPeroxisome proliferator-activated receptorInflammationGeneral MedicinePharmacologymedicine.disease_cause03 medical and health sciences0302 clinical medicinechemistryApoptosismedicinebiology.protein030211 gastroenterology & hepatologyViability assaymedicine.symptomOxidative stressmedicine.drugInternational Journal of Medical Sciences
researchProduct

Endotrophin, a pro-peptide of Type VI collagen, is a biomarker of survival in cirrhotic patients with hepatocellular carcinoma

2021

Aim: Type VI collagen, is emerging as a signaling collagen originating from different types of fibroblasts. A specific fragment of Type VI collagen, the pro-peptide, is also known as the hormone endotrophin. We hypothesized that this fibroblast hormone would be of particular relevance in cancer types with a high amount of fibrosis activity, namely for outcome in hepatocellular carcinoma (HCC) cirrhotic patients. Patients & methods: Plasma C6M, PRO-C6 and alphafeto-protein (AFP) were assessed in 309 patients with mixed etiologies (hepatitis C, hepatitis B, alcohol and nonalcoholic fatty liver) diagnosed as cirrhotics, cirrhotics with HCC, noncirrhotics and healthy controls. Progression-f…

collagen0301 basic medicinemedicine.medical_specialtyHepatocellular carcinomaextracellular matrixGastroenterology03 medical and health sciences0302 clinical medicineSDG 3 - Good Health and Well-beingFibrosisInternal medicinemedicineneoplasmsHepatologyEndotrophinbusiness.industryHazard ratioFatty liverbiomarkersCancerhepatocellular carcinomaHepatitis CExtracellular matrixHepatitis Bmedicine.diseasedigestive system diseases030104 developmental biologyOncologyHepatocellular carcinomaendotrophinBiomarker (medicine)/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being030211 gastroenterology & hepatologyCollagenbusinessBiomarkersResearch Article
researchProduct

Minimally Invasive Video-Assisted Thyroidectomy: Analysis of Complications From a Systematic Review

2019

Background. Nowadays, minimally invasive video-assisted thyroidectomy (MIVAT) is considered a safe and effective option. However, its complication rate has not been specifically discussed yet. The aim of this systematic review was enrolling a large number of studies to estimate early and late complications (transient and definitive, uni- and bilateral laryngeal nerve palsy; transient and definitive hypocalcemia; cervical hematoma; hypertrophic or keloid scar) of MIVAT compared with conventional technique. Methods. The review was performed according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) criteria in PubMed and Embase. Search terms were “minimally inva…

definitive complicationmedicine.medical_specialtybusiness.industrytransient complicationsmedicine.medical_treatmentreviewThyroidectomyVideo-Assisted SurgeryMIVATSurgery03 medical and health sciencesVideo assisted thyroidectomyPostoperative Complications0302 clinical medicineminimally invasive video-assisted thyroidectomy030220 oncology & carcinogenesisThyroidectomyHumansMinimally Invasive Surgical ProceduresMedicine030211 gastroenterology & hepatologySurgeryComplication ratebusinessconventional thyroidectomySurgical Innovation
researchProduct

Surveillance of Hepatocellular Carcinoma and Diagnostic Algorithms in Patients with Liver Cirrhosis

2016

<b><i>Background:</i></b> Hepatocellular carcinoma (HCC) is the most deadly complication of all major chronic liver diseases. Since early detection is the most significant determinant of overall survival, intense screening is of major importance. <b><i>Methods:</i></b> This overview is based on a systematic review of the available literature on HCC screening and surveillance in the PubMed database. <b><i>Results:</i></b> Over the last decades, major etiological risk factors were identified and the population at highest risk for the development of HCC was clearly defined. Screening in these patients has been repeatedly d…

education.field_of_studymedicine.medical_specialtyCirrhosismedicine.diagnostic_testbusiness.industryPopulationGastroenterologyMagnetic resonance imagingGold standard (test)Review Articlemedicine.disease03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisHepatocellular carcinomaRadiological weaponmedicineEtiology030211 gastroenterology & hepatologySurgeryRadiologyeducationbusinessComplication
researchProduct

Cuantificación de la fibrosis hepática mediante biomarcadores de imagen

2018

There is a need for early identification of patients with chronic liver diseases due to their increasing prevalence and morbidity-mortality. The degree of liver fibrosis determines the prognosis and therapeutic options in this population. Liver biopsy represents the reference standard for fibrosis staging. However, given its limitations and complications, different non-invasive methods have been developed recently for the in vivo quantification of fibrosis. Due to their precision and reliability, biomarkers' measurements derived from Ultrasound and Magnetic Resonance stand out. This article reviews the different acquisition techniques and image processing methods currently used in the evalu…

education.field_of_studymedicine.medical_specialtymedicine.diagnostic_testbusiness.industryLiver fibrosisPopulationMagnetic resonance imagingContext (language use)medicine.disease030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineFibrosisLiver biopsyClinical valuemedicine030211 gastroenterology & hepatologyRadiology Nuclear Medicine and imagingeducationIntensive care medicinebusinessReference standardsRadiología
researchProduct

Tumor de células de la granulosa extraovárico con mutación FOXL2. Diagnóstico diferencial morfológico e inmunohistoquímico

2020

Extraovarian granulosa cell tumor is a very uncommon tumor and the identification of a recurrent mutation in FOXL2 may be used as another diagnostic tool along with the classical morphological and immunohistochemical findings. Here, we report a new case of extraovarian granulosa cell tumor in a 57 years old female patient presented with a sub-hepatic mass and abdominal pain. Histopathological examination of the excised mass showed features of adult-type granulosa cell tumor with α-inhibin, calretinin, WT1, S100, CD99 and progesterone receptor immunoreactivity. A FOXL2 mutation was detected on molecular biology study. A final diagnosis was an extraovarian adult-type granulosa cell tumor. We …

endocrine systemPathologymedicine.medical_specialtyAbdominal painurogenital systemGranulosa cellCD99BiologyPathology and Forensic Medicine03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisFemale patientProgesterone receptormedicineImmunohistochemistry030211 gastroenterology & hepatologyDifferential diagnosisCalretininmedicine.symptomRevista Española de Patología
researchProduct

Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on topical therapy in ulcerative colitis

2020

Although most patients with ulcerative colitis should be given topical treatment, different studies have shown that they are underused in clinical practice. The purpose of this article is to answer 10 specific questions about which drugs are available for topical use in the treatment of ulcerative colitis, and their characteristics in terms of formulation, dosage, presentation, application and proximal distribution of rectal-administered drugs. The efficacy of available topical drugs and the benefits of combining different formulations and routes of administration, and their usefulness during disease remission are evaluated. Finally, a series of recommendations addressed to patients are giv…

glucocorticoidesmedicine.medical_specialtycolitisAdministration TopicalhumanosAnti-Inflammatory AgentsTopical treatmentmesalamina03 medical and health scienceschemistry.chemical_compound0302 clinical medicineMesalazineTopical treatmentmedicineMesalazinaHumansCorticosteroidsMesalamineGlucocorticoidsCrohn's diseasebusiness.industryAnti-Inflammatory Agents Non-Steroidalmedicine.diseaseantiinflamatoriosUlcerative colitisDermatologyClinical PracticechemistryUlcerative colitis030220 oncology & carcinogenesisDisease remission030211 gastroenterology & hepatologyColitis UlcerativeMesalazinebusiness
researchProduct

Impact of BMGIM Music Therapy on Emotional State in Patients with Inflammatory Bowel Disease: A Randomized Controlled Trial

2021

Este artículo se encuentra disponible en la siguiente URL: https://www.mdpi.com/2077-0383/10/8/1591 En este artículo de investigación también participan: María Josefa-Rodríguez-Morales, Ana Monzó-Gallego, José Luis Platero Armero y José Enrique de la Rubia Ortí. Este artículo pertenece al número especial "Novel Insight into the Diagnosis and Management of Crohn?s Disease". Background. Patients with inflammatory bowel disease (IBD) have a high prevalence of emotional disturbances which worsen the symptoms of the disease. As a therapeutic alternative that is part of a comprehensive care alongside medication, the Bonny Method of Guided Imagery and Music (BMGIM) music-assisted therapy has achie…

guided imagerymedicine.medical_specialtyMusic therapymusic therapylcsh:MedicineIntestinos - Enfermedades - Tratamiento.Inflammatory bowel diseaseArticlelaw.invention03 medical and health sciencesMusicoterapia.0302 clinical medicineQuality of life (healthcare)Randomized controlled triallawinflammatory bowel diseaseInternal medicineMedicine030212 general & internal medicineGuided imageryDepression (differential diagnoses)business.industrylcsh:RIntestines - Diseases - Treatment.General Medicinemedicine.diseaseanxietyMooddepressionAnxiety030211 gastroenterology & hepatologymedicine.symptombusinessMusic therapy.emotional aspectsJournal of Clinical Medicine
researchProduct

Grazoprevir/elbasvir for the immediate treatment of recently acquired HCV genotype 1 or 4 infection in MSM.

2020

Abstract Background In Europe, increases in HCV infection have been observed over the last two decades in MSM, making them a key population for recently acquired HCV. Alternative combinations of direct-acting antiviral agents against early HCV infection need to be assessed. Patients and methods In this pilot trial, MSM with recently acquired genotype 1 or 4 HCV infection were prospectively included and received 8 weeks of oral grazoprevir 100 mg and elbasvir 50 mg in a fixed-dose combination administered once daily. The primary endpoint was sustained virological response evaluated 12 weeks after the end of treatment (EOT) (SVR12). Secondary endpoints were the virological characterization of…

hepatitis C virusCyclopropanesMaleadverse eventmen who have sex with menHepacivirusmedicine.disease_causeSexual and Gender Minoritiesblood HIV RNA0302 clinical medicine[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesfollow-upClinical endpointMedicinePharmacology (medical)infections030212 general & internal medicinehepatitis ceducation.field_of_studySulfonamideshepatitis c rnaImidazolesvirus diseasesHepatitis Cvirologyhepatitis C virus genotype 13. Good healthEuropeInfectious DiseasesGrazoprevirRNA Viral030211 gastroenterology & hepatologyDrug Therapy CombinationMicrobiology (medical)medicine.medical_specialtyElbasvirGenotypeHepatitis C virusPopulationelbasvirAntiviral Agentsreinfection03 medical and health sciencesInternal medicineQuinoxalinesHumansHomosexuality MaleAdverse effecteducationplasmasuicideBenzofuransPharmacologybusiness.industrySurrogate endpointHIVgrazoprevirHepatitis C Chronicmedicine.diseaseAmidessurrogate endpoints[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/PharmacologyQuality of LifeCarbamatesbusinessThe Journal of antimicrobial chemotherapy
researchProduct

Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe

2018

All-oral direct-acting antiviral drugs (DAAs) for hepatitis C virus, which have response rates of 95% or more, represent a major clinical advance. However, the high list price of DAAs has led many governments to restrict their reimbursement. We reviewed the availability of, and national criteria for, interferon-free DAA reimbursement among countries in the European Union and European Economic Area, and Switzerland. Reimbursement documentation was reviewed between Nov 18, 2016, and Aug 1, 2017. Primary outcomes were fibrosis stage, drug or alcohol use, prescriber type, and HIV co-infection restrictions. Among the 35 European countries and jurisdictions included, the most commonly reimbursed …

hepatitis C virusHIV Infectionschemistry.chemical_compound0302 clinical medicineAntiviral Agents/economicsHIV-HCV co-infection030212 general & internal medicineReimbursementliver fibrosismedia_commonDasabuvirCoinfectionHealth PolicyGastroenterologyHepatitis C3. Good healthEuropeHepatitis C Chronic/complicationsInsurance Health Reimbursement030211 gastroenterology & hepatologySwitzerlandmedicine.drugmedicine.medical_specialtyHIV Infections/complicationsAntiviral AgentsDrug Costs03 medical and health scienceshepatitis C treatmentmedicineHumansmedia_common.cataloged_instanceEuropean UnionEuropean unionPWIDIntensive care medicineHepatitisdirect-acting antiviralHepatologybusiness.industryHepatitis C Chronicalcohol usemedicine.diseasereimbursementVirologyOmbitasvirchemistryParitaprevirRitonavirbusinesstreatment restrictionsThe Lancet Gastroenterology & Hepatology
researchProduct